Abstracts tagged "remission"

Abstract Number: 0844 • ACR Convergence 2021
Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort
Stephanie Keeling¹, Britney Jones², Jill Hall³, Joanne Homik⁴, Anthony Russell¹, Luck Lukusa⁵, Sasha Bernatsky⁶ and Walter Maksymowych⁷, ¹Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ²University of Alberta/University of Calgary, Edmonton, AB, Canada, ³Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) experience refractory disease and do not attain remission imparting worse long-term outcomes. We evaluated RA patients…
Abstract Number: 0522 • ACR Convergence 2021
Genetics of Rheumatoid Arthritis Remission; HLA-SE Associated with Remission in Anti-CCP Positive Patients
Marc Maurits¹, Samantha Jurado Zapata¹, Yann Abraham², Erik van den Akker¹, Anne Barton³, Philip Brown⁴, Andrew P Cope⁵, Isidoro Gonzalez-Alvaro⁶, Carl Goodyear⁷, Annette H.M van der Helm-van Mil¹, Xinli Hu⁸, Tom WJ Huizinga¹, Martina Johannesson⁹, Lars Klareskog¹⁰, Dennis Lendrem¹¹, Iain McInnes¹², Fraser Morton⁷, Caron Paterson⁷, Duncan Porter¹³, Arthur Pratt¹¹, Luis Rodriguez Rodriguez¹⁴, Daniela Sieghart¹⁵, Paul Studenic¹⁶, Suzanne Verstappen¹⁷, Leonid Padyukov⁹, Aaron Winkler¹⁸, John Isaacs¹⁹ and Rachel Knevel¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium, ³University of Manchester, Manchester, United Kingdom, ⁴Newcastle University, Newcastle, United Kingdom, ⁵King's College London, London, United Kingdom, ⁶Rheumatology Service. La Princesa University Hospital, Madrid, Spain, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Pfizer, Saint Peters, MO, ⁹Karolinska Institutet, Stockholm, Sweden, ¹⁰Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ¹¹Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ¹²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ¹³University of Glasgow, Bearsden, United Kingdom, ¹⁴Hospital Clinico San Carlos, Madrid, Spain, ¹⁵Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ¹⁶Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ¹⁷School of Social Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁸Pfizer, Cambridge, MA, ¹⁹Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) patients capable of reaching clinical remission potentially have a specific genetic profile that allows them to regain immune tolerance. The identification…
Abstract Number: 029 • 2020 Pediatric Rheumatology Symposium
Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis
Angela Chun¹, Lutfiyya Muhammad ² and Deirdre De Ranieri ³, ¹Lurie Children's Hospital, Chicago, Iowa, ²Northwestern University Feinberg School of Medicine, Chicago, ³Lurie Children's Hospital, Chicago, Illinois
Background/Purpose: The use of intra-articular corticosteroid (IAC) injections for Juvenile Idiopathic Arthritis (JIA) was extrapolated from its use in adult inflammatory joint diseases to achieve…
Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium
Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile
Sara Concha¹, Pamela Morales ², Eduardo Talesnik ¹ and Arturo Borzutzky ¹, ¹Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, ²Department of Pediatric, Clinica Las Condes, Santiago, Chile
Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
Abstract Number: L08 • 2019 ACR/ARP Annual Meeting
Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial
Siri Lillegraven¹, Nina Sundlisater ², Anna-Birgitte Aga ³, Joe Sexton ¹, Inge Christoffer Olsen ⁴, Hallvard Fremstad ⁵, Cristina Spada ⁶, Tor Magne Madland ⁷, Christian Høili ⁸, Gunnstein Bakland ⁹, Åse Lexberg ¹⁰, Inger Johanne Widding Hansen ¹¹, Inger Myrnes Hansen ¹², Hilde Haukeland ¹³, Maud-Kristine Aga Ljoså ¹⁴, Ellen Moholt ¹⁵, Till Uhlig ¹⁶, Daniel Solomon ¹⁷, Désirée van der Heijde ¹⁸, Tore Kvien ¹⁶ and Espen A Haavardsholm ¹⁵, ¹Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ³Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Ålesund Hospital, Helse Møre og Romsdal, Ålesund, Norway, ⁶Lillehammer Hosptial for Rheumatic Diseases, Lillehammer, Norway, ⁷Haukeland University Hospital, Bergen, Norway, ⁸Hospital Østfold HF, Moss, Norway, ⁹University Hospital of North Norway, Tromsø, Norway, ¹⁰Drammen Hospital, Vestre Viken HF, Drammen, Norway, ¹¹Sørlandet Hospital HF, Kristiansand, Norway, ¹²Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, ¹³Martina Hansens Hospital, Bærum, Norway, ¹⁴Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, ¹⁵Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ¹⁷Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ¹⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sustained remission is the goal of rheumatoid arthritis (RA) care, and more patients reach and maintain this state on conventional synthetic disease modifying anti-rheumatic…
Abstract Number: L11 • 2019 ACR/ARP Annual Meeting
Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Thomas W.J. Huizinga ⁴, Gustavo Citera ⁵, Clifton Bingham ⁶, Subhashis Banerjee ⁷, Benjamin Soule ⁸, Marleen Nys ⁹, Sean Connolly ¹⁰, Robert Wong ¹⁰, Kuan-Hsiang Gary Huang ⁷ and Roy Fleischmann ¹¹, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁶Johns Hopkins University, Baltimore, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Bristol-Myers Squibb, Princeton, New Jersey, ⁹Bristol-Myers Squibb, Braine L'Alleud, Belgium, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
Abstract Number: 1442 • 2019 ACR/ARP Annual Meeting
Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis
MASAOMI YAMASAKI¹, ¹Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan
Background/Purpose: However biological DMARDs (bDMARDs) and treatment strategies have improved the outcomes of rheumatoid arthritis (RA), it is unknown who can taper or stop bDMARDs…
Abstract Number: 1557 • 2019 ACR/ARP Annual Meeting
Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Daniela DiGuiseppe ², Anne Gitte Loft ³, Manuel Pombo-Suarez ⁴, Herman Mann ⁵, Ziga Rotar ⁶, Florenzo Iannone ⁷, Tore Kvien ⁸, Maria José Santos ⁹, Kari K. Eklund ¹⁰, Bjorn Gudbjornsson ¹¹, Catalin Codreanu ¹², Sema Yılmaz ¹³, Johan Askling ¹⁴, Carlos Sánchez-Piedra ¹⁵, Karel Pavelka ⁵, Matija Tomsic ¹⁶, Fabrizio Conti ¹⁷, Joe Sexton ¹⁸, Helena Santos ¹⁹, Nina Trokovic ²⁰, Thorvardur J Love ²¹, Ruxandra IONESCU ²², Yavuz Pehlivan ²³, Michael J. Nissen ²⁴, Gary Macfarlane ²⁵, Irene van der Horst-Bruinsma ²⁶, Stylianos Georgiadis ²⁷, Lykke Midtbøll Ørnbjerg ²⁸, Cecilie Heegaard Brahe ²⁸, Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁴Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁸Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹¹Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ¹⁴Karolinska Institutet, Stockholm, Sweden, ¹⁵Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁶Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ¹⁷Sapienza University of Rome, Rome, Italy, ¹⁸Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²⁰Helsinki University Central Hospital, Helsinki, Finland, ²¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²²SPITALUL CLINIC SFANTA MARIA, Bucharest, ²³Uludağ University, Bursa, Turkey, ²⁴University Hospital Geneva, Geneva, Switzerland, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁷DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Secukinumab represents a relatively new approach to treating patients with psoriatic arthritis (PsA) and has shown promising results in RCTs. However, there is a…
Abstract Number: 1684 • 2019 ACR/ARP Annual Meeting
Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual
Paolo Delvino ¹, Federica Sardanelli ², Pascal Cohen ³, Xavier Puéchal for the French Vasculitis Study Group ³, Luc Mouthon ³, Loic Guillevin ³ and Benjamin Terrier³, ¹Rheumatology Department, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Vercelli, Italy, ²Department of Internal Medicine , Clinical Immunology Unit of Genoa and Policlinico San Martino, Genova, Italy, ³National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) require glucocorticoids (GCs) and immunosuppressants (IS) to induce and maintain remission. At the era of highly…
Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting
6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Johan Askling ², Catalin Codreanu ³, Herman Mann ⁴, Anne Gitte Loft ⁵, Manuel Pombo-Suarez ⁶, Ziga Rotar ⁷, Tore Kvien ⁸, Maria José Santos ⁹, Anna Mari Hokkanen ¹⁰, Florenzo Iannone ¹¹, Bjorn Gudbjornsson ¹², Fatos Onen ¹³, Lennart Jacobsson ¹⁴, Ruxandra IONESCU ¹⁵, Karel Pavelka ⁴, Carlos Sánchez-Piedra ¹⁶, Matija Tomsic ¹⁷, Joe Sexton ¹⁸, Helena Santos ¹⁹, Jenny Österlund ²⁰, Alberto Cauli ²¹, Arni Jon Geirsson ²², Servet Akar ²³, Adrian Ciurea ²⁴, Gareth Jones ²⁵, Irene van der Horst-Bruinsma ²⁶, Cecilie Heegaard Brahe ²⁷, Stylianos Georgiadis ²⁸, Lykke Midtbøll Ørnbjerg ²⁷, Mikkel Østergaard ²⁹ and Merete Lund Hetland ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Karolinska Institutet, Stockholm, Sweden, ³Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁶Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁷UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ⁸Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Helsinki University Hospital, Helsinki, Finland, ¹¹Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ¹²Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ¹⁵SPITALUL CLINIC SFANTA MARIA, Bucharest, ¹⁶Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁷Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ¹⁸Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²⁰ROB-FIN registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²¹Universitá di Cagliari, Cagliari, Italy, ²²Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ²⁴University Hospital Zürich, Zürich, Switzerland, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁸DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³⁰DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…
Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Kuan-Hsiang Gary Huang ⁷, Sean Connolly ⁷, Yedid Elbez ⁸, Karissa Lozenski ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Princeton, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
Abstract Number: 2390 • 2019 ACR/ARP Annual Meeting
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Melanie Hagen¹, Koray Tascilar ², Michaela Reiser ³, Judith Haschka ⁴, Arnd Kleyer ⁵, Larissa Valor ⁶, Bernhard Manger ⁷, Georg Schett ⁸ and Jürgen Rech ⁹, ¹Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Karl Landsteiner Institute for Gastroenterology and Rheumatology, St. Vincent Hospital Vienna, II Medical Department, Vienna, Austria, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany, ⁷Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ⁸Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…
Abstract Number: 2511 • 2019 ACR/ARP Annual Meeting
What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study
Laura Coates¹, Danielle Robinson ², Ana-Maria Orbai ³, Uta Kiltz ⁴, Ying-Ying Leung ⁵, Penelope Palominos ⁶, Juan Cañete ⁷, Rossana Scrivo ⁸, Andra Balanescu ⁹, Emmanuelle Dernis ¹⁰, Sandra Talli ¹¹, Adeline Ruyssen-Witrand ¹², Lihi Eder ¹³, Maarten de Wit ¹⁴, Josef Smolen ¹⁵, Ennio Lubrano ¹⁶ and Laure Gossec ¹⁷, ¹University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital,, Singapore, Singapore, ⁶Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul,, Porto Alegra, Brazil, ⁷Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ⁸Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza Università di Roma,, Rome, Italy, ⁹Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ¹⁰Rheumatology Department, Le Mans Central Hospital, Le Mans, France, ¹¹Rheumatology Department, East-Tallinn Central Hospital, Tallinn, Estonia, ¹²Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, ¹³Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ¹⁴Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ¹⁵Medical University of Vienna, Vienna, Austria, ¹⁶15. Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ’Vincenzo Tiberio’, University of Molise, Campobasso, Italy, ¹⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: In psoriatic arthritis (PsA), the objective of treatment is remission or low disease activity (LDA), but there is little research into patients’ perception of…
Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Jun Kikuchi¹, Hironari Hanaoka ¹, Shuntaro Saito ¹, Tatsuhiro Oshige ¹, Kazuoto Hiramoto ¹, Yuko Kaneko ¹, Noriyasu Seki ², Hideto Tsujimoto ² and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…
Abstract Number: 2696 • 2019 ACR/ARP Annual Meeting
Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Ekaterina Alexeeva¹, Rina Denisova ², Tatyana Dvoryakovskaya ², Ksenia Isaeva ², Ivan Kriulin ², Alina Alshevskaya ³ and Andrey Moskalev ³, ¹National Medical Research Center of Children`s Health, Moscow, Russia, ²NMRCCH, Moscow, Russia, ³Biostatistics and Clinical Trials Center, Novosibirsk, Russia
Background/Purpose: Canakinumab (CAN) is an efficacious option for treatment of systemic juvenile idiopathic arthritis (sJIA). However, it is still disputable whether long-term therapy is efficacious…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].